A Phase 4 interventional study of Fexofenadine in Rhinitis, Allergic, Perennial, sponsored by Sanofi. Completed at 1 site in Philippines. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2009-09-15.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine the safety and efficacy of Fexofenadine (Telfast®) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic rhinitis.
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
This study's enrollment of 264 is above the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Browse Rhinitis, Allergic, Perennial studies →Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Fexofenadine
Drug: Fexofenadine
Fexofenadine: One 30 mg Tablet once daily for two weeks
Patient's assessment of symptoms and drug activity (Total symptom scores)
Time frame: At baseline, D 7 and D 14
Physician's assessment of symptoms and drug activity (Total symptom scores)
Time frame: At D 14
AE and SAE collection
Time frame: From the signature of the informed consent up to the end of the study
The record gives a start of Mar 2002 and a primary completion of Dec 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexofenadine
Rhinitis, Allergic, Perennial →